Omeprazole-based dual and triple therapy for the treatment of Helicobacter pylori infection in peptic ulcer disease: A randomized trial

被引:23
|
作者
Pieramico, O
Zanetti, MV
Innerhofer, M
Malfertheiner, P
机构
[1] UNIV MAGDEBURG,DEPT GASTROENTEROL HEPATOL & INFECT DIS,D-39106 MAGDEBURG,GERMANY
[2] OSPED GEN,DEPT MICROBIOL,I-39012 MERANO,ITALY
关键词
D O I
10.1111/j.1523-5378.1997.tb00065.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives, it was our goal to evaluate the efficacy and safety and patient compliance with omeprazole-based dual and triple therapy for eradication of Helicobacter pylori in peptic ulcer disease. Materials and Methods. One hundred seventy-five consecutive patients with H. pylori infection and associated active peptic ulcer were included. H. pylori infection was assessed by rapid urease test and histological analysis. Patients were randomized among three treatments: group 1 (56 patients): omeprazole, 20 mg bid, and amoxicillin, 1 gm bid, for 2 weeks; group 2 (61 patients): omeprazole, 20 mg bid, plus amoxicillin, 1 gm bid, and metronidazole, 500 mg bid, for 1 week; and group 3 (58 patients): omeprazole, 20 mg bid, plus amoxicillin, 1 gm bid, and clarithromycin, 500 mg bid, for 1 week. Ulcer healing and cure of infection were evaluated at 4 to 6 weeks after cessation of therapy. Eradication rate was calculated per-protocol and by an intention-to-treat analysis. Results. At posttreatment endoscopy, duodenal ulcer was healed in 98.3% of patients. Eleven patients (6%) were lost to follow-up. H. pylori Infection was treated successfully in 55% (95% confidence interval [CI] = 41%-69%) of patients of group 1; 86% (95% CI = 77%-95%) of group 2 (p < .001 vs. group 1); and 93% (95% CI = 85%-100%) of group 3 (p < .001 vs. group I). On intention-to-treat analysis, eradication was 52%, 80%, and 86% in groups 1, 2, and 3, respectively. A good compliance was observed in more than 90% of patients of all groups. Side effects were reported by 7% of patients in group 1, 9% in group 2, and 11% in group 3. None of the patients stopped therapy because of side effects. Conclusions. Dual-therapy omeprazole-amoxicillin for 2 weeks is associated with significantly lower eradication rate than is 1-week omeprazole-based triple therapies. Triple therapy is well-tolerated and produces side effects similar to those of dual therapy. The highest cure rate of H. pylori infection was achieved with triple therapy of omeprazole, amoxicillin, and clarithromycin for 1 week.
引用
下载
收藏
页码:92 / 97
页数:6
相关论文
共 50 条
  • [1] A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori
    Chu, KM
    Choi, HK
    Tuen, HH
    Law, SYK
    Branicki, FJ
    Wong, J
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (09): : 1436 - 1442
  • [2] LIMITED EFFICACY OF OMEPRAZOLE-BASED DUAL AND TRIPLE HELICOBACTER-PYLORI THERAPY - A RANDOMIZED TRIAL EMPLOYING OPTIMAL DOSING
    LAINE, L
    STEIN, C
    NEIL, G
    GASTROENTEROLOGY, 1995, 108 (04) : A142 - A142
  • [3] LIMITED EFFICACY OF OMEPRAZOLE-BASED DUAL AND TRIPLE THERAPY FOR HELICOBACTER-PYLORI - A RANDOMIZED TRIAL EMPLOYING OPTIMAL DOSING
    LAINE, L
    STEIN, C
    NEIL, G
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1995, 90 (09): : 1407 - 1410
  • [4] Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer
    Kim, HS
    Lee, DK
    Kim, KH
    Jeong, YS
    Kim, JW
    Seo, JI
    Baik, SK
    Kwon, SO
    Cho, MY
    JOURNAL OF GASTROENTEROLOGY, 2001, 36 (02) : 96 - 102
  • [5] Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children
    Kato, S
    Takeyama, J
    Ebina, K
    Naganuma, H
    PEDIATRICS, 1997, 100 (01) : E3
  • [6] Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer
    Hyun Soo Kim
    Dong Ki Lee
    Kwang Hyun Kim
    Yon Soo Jeong
    Jae Woo Kim
    Jeong In Seo
    Soon Ku Baik
    Sang Ok Kwon
    Mee Yon Cho
    Journal of Gastroenterology, 2001, 36 : 96 - 102
  • [7] Role of gastroduodenal disease and age on the outcome of omeprazole-based dual and triple therapy for Helicobacter pylori eradication.
    Pieramico, O
    Zanetti, MV
    GASTROENTEROLOGY, 1997, 112 (04) : A258 - A258
  • [8] Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer
    Yang, KC
    Wang, GM
    Chen, JH
    Chen, TJ
    Lee, SC
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2003, 102 (12) : 857 - 862
  • [9] A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia
    Laurent, J
    Mégraud, F
    Fléjou, JF
    Caekaert, A
    Barthélemy, P
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (11) : 1787 - 1793
  • [10] Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease
    Hawkey, CJ
    Atherton, JC
    Treichel, HC
    Thjodleifsson, B
    Ravic, M
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) : 1065 - 1074